Liquid biopsy technology for early cancer detection is here—and it's transforming how we approach prevention, treatment, and the pursuit of better outcomes.Dr. Richard Bernert of Precision Epigenomics introduces EPISEEK™, a groundbreaking liquid biopsy that uses epigenomic analysis to detect DNA changes associated with over 60 types of cancer.The landscape of cancer detection and prevention is shifting rapidly—mirroring the accelerating environmental factors linked to rising cancer incidence. Now more than ever, proactive action is essential.Tune in to learn how epigenomics plays a critical role in early cancer detection and how this knowledge can save lives. Gaining early insight—for yourself and those you love—undoubtedly leads to better outcomes.Want to learn more about EPISEEK™? Check out precision-epigenomics.com for more information about liquid biopsies.0:00 - Introduction to Rubin On Point0:45 - Why Early Cancer Detection Matters2:10 - Meet Dr. Richard Bernert & Precision Epigenomics5:05 - The Global Cancer Crisis: Why Detection Is Key8:20 - Current Cancer Screening Limitations10:45 - How Liquid Biopsy Works14:30 - Epigenetics 101: What You Need to Know17:15 - The Future of Cancer Screening: 60+ Cancer Types Detected21:30 - Who Should Consider This Test?24:00 - How to Access Epic’s Liquid Biopsy Test27:45 - Minimal Residual Disease & Long-Term Monitoring30:20 - Potential Impact on Patient Outcomes32:45 - How You Can Help Prevent Cancer35:00 - What’s Next for Early Cancer Detection?